These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37535994)

  • 21. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
    Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    Yucer N; Ahdoot R; Workman MJ; Laperle AH; Recouvreux MS; Kurowski K; Naboulsi DJ; Liang V; Qu Y; Plummer JT; Gayther SA; Orsulic S; Karlan BY; Svendsen CN
    Cell Rep; 2021 Dec; 37(13):110146. PubMed ID: 34965417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
    Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
    Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    Amit A; Sabo E; Zohar Y; Trugman E; Pranovich I; Reiss A; Matanes E; Klorin G
    Int J Gynecol Pathol; 2018 Sep; 37(5):460-467. PubMed ID: 28863070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
    Abay M; Ozgen L; Yalcin Y; Ozerkan K
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.
    Bartlett TE; Chindera K; McDermott J; Breeze CE; Cooke WR; Jones A; Reisel D; Karegodar ST; Arora R; Beck S; Menon U; Dubeau L; Widschwendter M
    Nat Commun; 2016 May; 7():11620. PubMed ID: 27216078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
    Crum CP; Drapkin R; Kindelberger D; Medeiros F; Miron A; Lee Y
    Clin Med Res; 2007 Mar; 5(1):35-44. PubMed ID: 17456833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J; Shi JL; Shen DH; Chen YX; Song QJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
    Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
    J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
    Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
    J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
    Sakurada S; Watanabe Y; Tokunaga H; Takahashi F; Yamada H; Takehara K; Yaegashi N
    Jpn J Clin Oncol; 2018 Sep; 48(9):794-798. PubMed ID: 29982601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Fallopian Tubes in the Development of Ovarian Cancer.
    Corzo C; Iniesta MD; Patrono MG; Lu KH; Ramirez PT
    J Minim Invasive Gynecol; 2017 Feb; 24(2):230-234. PubMed ID: 28007588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.